Gravar-mail: ATIM-39. PHASE 2 OPEN-LABELED STUDY OF ADJUVANT TEMOZOLOMIDE PLUS TUMOR TREATING FIELDS PLUS PEMBROLIZUMAB IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (2-THE-TOP)